Skip to main content

José Raul Herance Camacho

Institutions of which they are part

Head of group
Molecular Medical Imaging
Vall Hebron Institut de Recerca

José Raul Herance Camacho

Institutions of which they are part

Head of group
Molecular Medical Imaging
Vall Hebron Institut de Recerca

Projects

Eritrocitos sintéticos para la vigilancia del virus de la gripe

IP: Eva Baldrich Rubio
Collaborators: Andres Antón Pagarolas, José Raul Herance Camacho, Tomàs Pumarola Suñé, Cristina Andrés Vergés
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 100000
Reference: IU68-017255
Duration: 23/07/2020 - 22/04/2022

Immunomodulació de la resistència a la insulina en teixit adipós i els seus efectes sobre la resistencia a la insulina en miocardi

IP: José Raul Herance Camacho
Collaborators: Julia Baguña Torres, Laia Perez Lasarte, Genoveva Arqueros Sánchez
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 88500.55
Reference: SLT008/18/00113
Duration: 02/09/2019 - 31/12/2021

Administración tópica ocular de inhibidores de DPP-4: una nueva estrategia terapéutica para la retinopatía diabética

IP: Cristina Hernández Pascual
Collaborators: Marta García Ramírez, J. Bruno Montoro Ronsano, Ana Boixadera Espax, José Raul Herance Camacho, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 119900
Reference: DTS18/00163
Duration: 01/01/2019 - 30/06/2021

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies

IP: José Raul Herance Camacho
Collaborators: Alvaro Jesus Valverde Moya, Carolina Aparicio Gomez, Julia Baguña Torres, Emily Betancourt Fernández, Jana Vidal Otero, Cristina Gamez Cenzano
Funding agency: The Innovative Medicines Initiative
Funding: 514560
Reference: IMMUNE-IMAGE_IMI22018
Duration: 01/10/2019 - 30/09/2024

Related news

The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

Related professionals

Joan Piñas Massó

Joan Piñas Massó

Biomedical Research in Cancer Stem Cells
Read more
Gastelum Varela, Graciela

Gastelum Varela, Graciela

Predoctoral researcher
Diabetes and Metabolism
Read more
Francesc Casellas Jordá

Francesc Casellas Jordá

Physiology and Pathophysiology of the Digestive Tract
Read more
Garcia Arabehety, Julia

Garcia Arabehety, Julia

Research technician
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.